‘Hope on the horizon' as drugs assessed for Alzheimer's prevention
Some 138 treatments are being assessed in clinical trials.
A third of drugs currently being trialled are 'repurposed' medications that are already being used to tackle other diseases, including diabetes, multiple sclerosis and cholesterol, according to the new review.
One such trial is assessing whether semaglutide, the main ingredient for the weight loss and diabetes drug Ozempic and weight loss drug Wegovy, can slow the progression of dementia.
And four late-stage trials are looking at preventing disease.
Experts said that drugs targeting amyloid protein build up in the brain, such as lecanemab and donanemab, are 'only one part of the overall strategy' as they expressed excitement over the variety of new drugs, which are being tested among patients.
The new review of Alzheimer's disease in clinical trials in 2025 found 182 clinical trials assessing the impact of 138 drugs.
The number of trials represents an 11% increase on the previous year, according to the review, which was led by an expert from the University of Nevada in the US and has been published in the journal Alzheimer's and Dementia: Translational Research and Clinical Interventions.
Commenting on the paper, Dr Sheona Scales, director of research at Alzheimer's Research UK, said: 'This year has really given us real cause for optimism.'
She said that as well as more drugs coming through the pipeline, the treatment targets are 'more diverse' and 'looking at all stages of the disease'.
She added: 'What this paper is showing us is that the pipeline of drug development is growing, it's diversifying and accelerating.'
'This latest report shows us that there is hope on the horizon for people with Alzheimer's, building on lecanemab and donanemab.'
Dr Emma Mead, chief scientific officer of the Oxford Drug Discovery Institute, added: 'Today we are at a tipping point in dementia research as we understand more and more about the diseases that drive dementia.
'This gives us opportunities to slow and ultimately stop this devastating condition and today's announcement demonstrates that researchers are able to translate these understandings towards potential new treatments.'
James Rowe, professor of cognitive neurology at the University of Cambridge and consultant neurologist, said: 'What strikes me is not just the number of new drugs, which is increasing year on year, but their range of targets (and) the range in which they work, giving us multiple shots on goal.'
On the drugs which are being investigated for the prevention of disease, Prof Rowe said: 'One of the most exciting things of this report is the number of large-scale late-stage trials on prevention.
'And the aspiration to prevent, not just treat, is starting to be seen in the figures we see in these charts today.'
He added: 'One way this can work is you take a treatment that you show to be working in people with symptoms with the illness, and then you simply bring it forward by some years.
'The ones that are in trial at the moment are really… bringing forward an effective treatment to earlier stage.'
For instance, people with a genetic risk of Alzheimer's could receive some drugs earlier to see if they protect against the disease.
On the repurposing of current drugs, Dr Mead said that it can usually take 10 to 15 years for new drugs to be tested and approved for use.
'Being able to repurpose drugs licensed for other health conditions could help to accelerate progress and help to open up other avenues to prevent or treat dementia causing diseases,' she said.
'A really promising example of this is the drug semaglutide, which is currently being trialled in people with mild cognitive impairment.'
Meanwhile, academics said lecanemab and donanemab, which can be used for treating mild cognitive impairment in Alzheimer's patients, are an 'important first step' in the battle against the disease.
The treatments were initially approved for UK use by regulators but then deemed not cost-effective for NHS use.
The National Institute for Health and Care Excellence (Nice) is taking more evidence on donanemab and lecanemab and is expected to announce its decision in the summer.
Dr Scales added: 'Lecanemab and donanemab have represented a huge leap forward in our understanding and ability to be able to treat Alzheimer's disease.
'What they've done is they've proved that we're able to modify the course of Alzheimer's disease, and what that has done is opened up the door to future treatments that we hope are more effective, easier to deliver and and able to deliver for our patients.'
She said studies are showing 'even more complexities' around Alzheimer's and that in the future, people may be treated with a combination of drugs, depending on when they are diagnosed and the type of dementia they have.
Dr Richard Oakley, associate director of research at Alzheimer's Society, said: 'This paper shows that 2025 is shaping up to be a landmark year for Alzheimer's disease drug development.
'With more trials under way than ever before and more drugs entering the pipeline, there is hope on the horizon for the nearly one million people living with dementia in the UK.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mirror
7 hours ago
- Daily Mirror
Only people with hawk eyes can solve this football puzzle in under 60 seconds
Brainteasers are great for maintaining sharpness and concentration so here's a particularly tricky example only the most eagle-eyed can solve in under a minute With the Fifa Club World Cup around the corner, it's time for a fiendishly difficult brainteaser. Five footballs have been cleverly concealed within a picture of the pitch, presenting a challenge to even the most avid puzzle lovers. The brainteaser was created by Live Football Tickets, which said it takes readers 1 minute 23 seconds on average to complete. It claimed one in four people struggled to complete it altogether, challenging Mirror Online readers to get the job done in under 60 seconds. Don't worry, however - if the quiz proves too difficult, the answer can be found at the bottom of the article. Brainteasers prove popular because people enjoy the satisfaction of cracking puzzles and giving their mind a workout at the same time. Puzzles can enhance a range of skills including focus, logic, observation and reasoning too. They can also help you to switch off from daily stresses and strains, giving your brain a welcome sense of relief. So was your mind is sharp enough to beat the clock and find the hidden footballs? The answers are circled below. Brain workouts have been shown to help reduce the risk of dementia, with research showing 40 per cent of cases are preventable. The condition is a set of symptoms caused by different diseases, for example Alzheimer's, which can damage the brain and over time can affect memory, problem-solving, language and behaviour. Although ageing is one of the biggest risk factors for developing the condition, evidence shows that there are things you can do to reduce the risk. With regular practice, puzzles can help build up "cognitive reserve", which is a person's ability to cope with dementia, and is built up by keeping the brain active. The more cognitive reserve a person has "the longer it takes for any diseases in their brain to cause problems with everyday tasks," according to experts from the Alzheimer's Society. "People with a smaller cognitive reserve are at a higher risk of getting dementia in their lifetime," a spokesman from the charity added. "Our brains, like any other muscle in our bodies, require exercise to stay sharp," added psychologist Neha Cadabam. "Daily brainteasers serve as a mental workout, engaging different cognitive processes and pathways, which can have a remarkable impact on cognitive function, especially as we age. "Taking a moment to challenge our brains with a brain teaser can feel like a welcome mental respite," said the executive director at Cadabams Hospitals. "But beyond the immediate satisfaction of solving a puzzle, these little brain teasers might be doing a lot more for us than we realise."
Daily Mail
10 hours ago
- Daily Mail
EXCLUSIVE Exposed: 'DIY Ozempic' sellers putting lives at risk by peddling super cheap but super dangerous self-mixing weight loss drugs in booming black market
Cheap 'Do It Yourself Ozempic' is being sold across Britain in a booming black market that puts lives at risk, a Daily Mail investigation has found. Scores of dealers based in the UK and China are using social media to openly advertise their cut-price illegal fat jabs to vulnerable people.
The Courier
16 hours ago
- The Courier
MARTEL MAXWELL: Dundee 'weight-loss wave' has me tempted by shortcuts
As summer approaches and holidays are planned, it is not unusual to notice a friend – or maybe two – looking fabulous. You do a double take when you see them – they look younger, fresher and thinner. The kind of dramatic weight loss that is transformative. Middle-age spread, pot belly, and puffy face gone. But here's the thing. And it's quite a thing. I'm double taking all the time. Give me any gathering of people in Dundee – school pick-up, kids' football match or a night out – and it's like a Slimming World magazine. Many will have found that oft elusive motivation to shed pounds (we all know how it works), to eat less and move more. Others – and not just the ones who admit to it – will have taken the short cut of injecting the new, increasingly-prominent, weight-loss drugs which suppress appetite and work to shift excess fat. More power to both camps – no judgement. But it's getting a bit Twilighty. It's like body snatchers are sneaking down to Dundee as night falls, replacing the lumpy and bumpy with Instagram-edited version of themselves – all flat stomachs and cheekbones. Regular readers of my column will know I've touched on this before, including last year when I discussed the Ozempic boom. I told you about a friend who admitted she was on the weight-loss jabs. She all but tapped her nose as we looked around the ladies' charity lunch we were at and said: 'Mark my words, women here are on it.' She told me she'd developed a sixth sense in telling who was on the medication. My friend was brilliantly honest, explaining how she paid for the jabs and how she couldn't shift the middle-aged spread which had taken her from a size 10 to 14. No clothes fitted and it was getting her down. She quickly lost a stone with the jabs but also admitted they affected her mood and made her a bit sick for the first few weeks. Another friend who's gone from a size 16 to 10 says she has had no side effects. She has more energy and claims the jabs took away her desire to drink as much alcohol, which was becoming a daily few glasses of wine after work. Fast forward eight months and sudden transformations are everywhere. I have also noticed an increase in people committing to sport, which is great. One friend is wild swimming twice a week while another is running ultra marathons. And one has even started her own CrossFit business – PeaceFit in Wormit. Many mutual friends attend her classes and look awesome – stronger, fitter and toned. I've noticed couples losing weight together. Going back to the jabs, I suppose it's too easy for the muffin tops like me to point a finger and say everyone's on them. But who wouldn't want a quick fix? A stone down for summer? The reintroduction of a bikini following a decade of covering up after kids and – if I'm entirely honest – dieting and sporadic exercise interspersed with occasional gluttony… I'm tempted myself. However, if something seems too good to be true, maybe, just maybe, it is. The jury is still out, with research pointing to the possibility of health complications involved with the jabs. This can be counter-argued with the fact obesity can cause diabetes, heart problems and cancer. Shifting weight if you're over 40 has the magical plus of shifting a few years in appearance too – puffy faces and pot bellies begone. Some of the people I'm seeing seem to have had a magical elixir of youth. If I sound envious, I probably am. Let me know if you've seen a younger, slimmer Dundee – and maybe even if you've taken a shortcut yourself. Bon appétit!
